Skip to content

Author

K. Thakkar

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.

BACKGROUND Respiratory syncytial virus (RSV) is a common virus causing severe illness in adults. RSV prefusion F protein subunit (RSVpreF) vaccine was approved by the Singapore Health Sciences Authority for adults aged 18-59 years at increased risk and for adults aged ≥ 60 years, to prevent RSV-associated lower respira...

K. Thakkar, A. Shajarizadeh, Nishu Gaind et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.